Skip to main content
SpringerLink
Log in
Book cover

Heart Failure in Clinical Practice pp 337–352Cite as

Device Therapy in Heart Failure

  • Chapter
  • First Online:

  • 1613 Accesses

Abstract

The last three decades have seen major advances in the pharmacological treatment of patients with heart failure. ACE inhibitors, beta blockers, Spironolactone and ARB’s have all been shown to improve symptoms, and prolong life, by a reduction in the risk of sudden cardiac death (SCD) and the risk of death due to progressive heart failure. These treatments constitute what is termed optimal medical treatment. Nevertheless, despite optimal medical treatment patients with heart failure remain at increased risk of SCD and death due to progressive heart failure. In addition, many patients remain symptomatic in NYHA Classes II, III or even IV.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. The antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.

    Article  Google Scholar 

  2. Kuck KH, Cappato R, Siebels J, Rüppel R. Defibrillators in patients resuscitated from cardiac arrest: The Cardiac Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.

    Article  PubMed  CAS  Google Scholar 

  3. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-1302.

    Article  PubMed  CAS  Google Scholar 

  4. Connolly AP, Hallstrom R, Cappato EB, et al.; on behalf of the investigators of the AVID, CASH and CIDS studies. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071-2078.

    Google Scholar 

  5. Owen A. How should the efficacy of novel treatments be assessed in survival trials? Int J Cardiol. 2007;120:297-300.

    Article  PubMed  CAS  Google Scholar 

  6. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statist Med. 2002;21:1539-1558.

    Article  Google Scholar 

  7. Daubert JP, Zareba DS, Cannom DS, et al.; for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-1365.

    Google Scholar 

  8. Mark DB, Anstrom KJ, Sun JL, et al.; for the Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008;359:999-1008.

    Google Scholar 

  9. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:2820-2840.

    Google Scholar 

  10. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J. 2008:29;2388-2442.

    Google Scholar 

  11. Moss AJ, Zareba W, Jackson Hall W, et al.; for the multicentre automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.

    Google Scholar 

  12. Wilber DJ, Zareba W, Hall J, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-1084.

    Article  PubMed  Google Scholar 

  13. Kadish A, Dyer A, Daubert JP, et al.; for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.

    Google Scholar 

  14. Bardy GH, Kerry LL, Daniel BM, et al.; for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.

    Google Scholar 

  15. Hohnloser SH, Kuck KH, Dorian P, et al.; on behalf of the DINAMIT Investigators. Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-4288.

    Google Scholar 

  16. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292(23):2874-2879.

    Article  PubMed  CAS  Google Scholar 

  17. Bristow MR, Saxon LA, Boehmer, J et al.; for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an Implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.

    Google Scholar 

  18. Strickberger SA, Hummel JD, Bartlett MC, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia – AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712.

    Article  PubMed  Google Scholar 

  19. Poole JE, Johnson GW, Hellhamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009-1017.

    Article  PubMed  CAS  Google Scholar 

  20. Køber L, Torp-Pedersen C, McMurray JJV, et al.; for the Dronedarone Study Group. Increased mortality after dromedaries. Therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.

    Google Scholar 

  21. Cazeau S, Leclercq C, Lavergne T, et al.; for the multisite stimulation in cardiomyopathies (MUSTIC) study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-880.

    Google Scholar 

  22. Auricchio A, Stellbrink C, Sack S, et al.; for the Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-2033.

    Google Scholar 

  23. Abraham WT, Fisher WG, Smith AL, et al.; for the MIRACLE study group. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.

    Google Scholar 

  24. Cleland JGF, Daubert J-C, Erdmann E, et al.; for the Cardiac Resynchronization – Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.

    Google Scholar 

  25. Cleland JGF, Daubert J-C, Erdmann E, et al.; on behalf of the CARE-HF Study Investigators. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure (the Cardiac REsynchronization-Heart Failure (CARE-HF) trial extension phase). Eur Heart J. 2006;27:1928-1932.

    Google Scholar 

  26. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA. 2003;289(20):2685-2694.

    Article  PubMed  Google Scholar 

  27. Higgins SL, Hummel JD, Imran K, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459.

    Article  PubMed  Google Scholar 

  28. Abraham WT, Young JB, Leon AR, et al.; on behalf of the Multicenter InSync ICD II Study Group. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868.

    Google Scholar 

  29. Lam S, Owen A. Combined resynchronization and defibrillation therapy in left ventricular dysfunction: bayesian network meta-analysis of randomized controlled trials. BMJ. 2007;335:925-934.

    Article  PubMed  Google Scholar 

  30. Maisch B, Soler-Soler J, Hatle L, et al. The ESC Textbook of Cardiovascular Medicine. In: Camm AJ, Luscher TF, Serruys PW, eds. Oxford: Blackwell Publishing; 2006.

    Google Scholar 

  31. Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-2616.

    Article  PubMed  Google Scholar 

  32. Henein MY, Amadia A, O’Sullivan C, Coats A, Gibson D. ACE inhibitors unmask incoordinate diastolic wall motion in restrictive left ventricular disease. Heart. 1996;76:326-331.

    Article  PubMed  CAS  Google Scholar 

  33. Owen A, Cox S. Diagnosis of heart failure in elderly patients in primary care. Eur J Heart Failure. 2001;3:79-81.

    Article  CAS  Google Scholar 

  34. Rathore SS, Yongfeiwang MPH, Krumholz HR. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.

    Article  PubMed  CAS  Google Scholar 

  35. Hsu L-F, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.

    Article  PubMed  CAS  Google Scholar 

  36. The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and vvi implantable defibrillator (david) trial. JAMA. 2002;288(24):3115-3123.

    Article  Google Scholar 

  37. Cleland JGF, Daubert JC, Erdmann E, et al.; on behalf of the CARE-HF study Steering Committee and Investigators. The CARE-HF study CArdiac REsynchronisation in Heart Failure study/rationale, design and end-points. Eur J Heart Failure. 2001;3:481-489.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Princess of wales Hospital, Bridgend, UK

    Andrew Owen

Authors
  1. Andrew Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Owen .

Editor information

Editors and Affiliations

  1. Thorney Crescent 27, Battersea, London, SW11 3TT, United Kingdom

    Michael Y. Henein

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer London

About this chapter

Cite this chapter

Owen, A. (2010). Device Therapy in Heart Failure. In: Henein, M. (eds) Heart Failure in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-84996-153-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-84996-153-0_19

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-152-3

  • Online ISBN: 978-1-84996-153-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation